Nuclear factor erythroid 2-related factor 2 (NFE2L2) Antibody (FITC)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Nuclear factor erythroid 2-related factor 2 (NFE2L2) Antibody (FITC) is a Rabbit Polyclonal antibody conjugated to FITC for the detection of Human NFE2L2.
Documents del producto
Product specifications
Category | Primary Antibodies |
Immunogen Target | Nuclear factor erythroid 2-related factor 2 (NFE2L2) |
Host | Rabbit |
Reactivity | Human |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Polyclonal |
Conjugation | FITC |
Isotype | IgG |
Purity | > 95% |
Purification | Purified by Protein G chromatography. |
Size 1 | 50 µl |
Size 2 | 100 µl |
Size 3 | 200 µl |
Size 4 | 1 ml |
Form | Liquid |
Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol. |
Availability | Shipped within 5-10 working days. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | Q16236 |
Gene ID | 4780 |
NCBI Accession | NM_006164.4 |
OMIM | 600492 |
Background | Antibody anti-NFE2L2 |
Status | RUO |
Descripción
Related Products

Human NFE2L2 (Nuclear Factor, Erythroid Derived 2 Like 2) ELISA Kit
Ver Producto
Rat Nfe2l2 (Nuclear Factor, Erythroid Derived 2 Like Protein 2) ELISA Kit
Ver Producto
NFE2L2 antibody
NRF2, also named as NFE2L2, belongs to the bZIP family and CNC subfamily. It is a transcription activator that binds to antioxidant response(ARE) elements in the promoter regions of target genes. NRF2 is important for the coordinated up-regulation of genes in response to oxidative stress. It may be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.Nrf2 is a key player in the regulation of genes encoding for many antioxidative response enzymes.The expression of NRF2 may be induced under oxidative stress(PMID:14567983).In lung cancer, Nrf2 activation in malignant cells has been associated with tumor progression and chemotherapy resistance(PMID:20534738). Identifying patients with abnormal NRF2 expression may be important for selection for chemotherapy in NSCLC.
Ver Producto